⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233379 | 0.82 | — | — | |
| SCHEMBL15847476 | 0.81 | — | — | |
| SCHEMBL5964839 | 0.73 | — | — | |
| SCHEMBL25286603 | 0.71 | — | — | |
| SCHEMBL836668 | 0.69 | — | — | |
| SCHEMBL8588368 | 0.67 | RAB9A (0.38) | — | |
| SCHEMBL11573275 | 0.67 | — | — | |
| SCHEMBL8188563 | 0.67 | TSHR (0.39) | — | |
| SCHEMBL2698476 | 0.67 | — | — | |
| SCHEMBL8991796 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580201-A2 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | Rhodes Technologies (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154827-A2 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | RHODES TECHNOLOGIES (US) | 2011-12-15 | — | — | WO | claimed |
| CN-112689634-B | SMAD3 inhibitors | 莫扎制药有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-111558049-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-111569086-B | Methylene carbamate linkers for use with target-drug conjugates | 西雅图基因公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118201946-A | Lipidated polymyxin analogues | 奥克兰联合服务有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-110914240-B | Norbornenone compounds releasing carbon monoxide | 奥塔哥创新有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117396232-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20230295215-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2023-09-21 | — | — | US | disclosed |
| CN-116063515-A | anti-FCRH 5 antibodies | 基因泰克公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2006050264-A1 | CATIONIC CERAMIDES, AND ANALOGS THEREOF, AND THEIR USE FOR PREVENTING OR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060069092-A1 | Pharmaceutical compositions for the treatment of diseases related to neurotrophines | MIMETECH S.R.L. (IT) | 2006-03-30 | — | — | US | disclosed |
| EP-1542991-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | Euro-Celtique, S.A. (LU) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005046594-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1525308-A2 | METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |